Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Breast Cancer

  Free Subscription


05.08.2019

3 Am J Surg
3 Ann Oncol
2 Ann Surg
8 Ann Surg Oncol
6 Anticancer Res
5 BMC Cancer
1 Br J Cancer
3 Breast Cancer
2 Breast Cancer Res
7 Breast Cancer Res Treat
3 Breast J
2 Cancer
2 Cancer Chemother Pharmacol
3 Clin Breast Cancer
3 Clin Cancer Res
1 Eur J Cancer
1 Eur J Surg Oncol
1 Eur Radiol
1 Int J Cancer
1 J Clin Oncol
1 Nature
2 NPJ Breast Cancer
1 Oncogene
2 Oncol Rep
3 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Surg

  1. KILLELEA BK, Gallagher EJ, Feldman SM, Port E, et al
    The effect of modifiable risk factors on breast cancer aggressiveness among black and white women.
    Am J Surg. 2019 Jul 18. pii: S0002-9610(19)30187.
    PubMed     Text format     Abstract available

  2. PLICHTA JK, Thomas SM, Sergesketter AR, Greenup RA, et al
    Clinical and pathological stage discordance among 433,514 breast cancer patients.
    Am J Surg. 2019 Jul 18. pii: S0002-9610(19)30099.
    PubMed     Text format     Abstract available

  3. BROMAN K, Sun W, Zhou JM, Fridley B, et al
    Outcomes of selective whole breast irradiation following lumpectomy with intraoperative radiation therapy for hormone receptor positive breast cancer.
    Am J Surg. 2019 Jul 17. pii: S0002-9610(19)30270.
    PubMed     Text format     Abstract available


    Ann Oncol

  4. BURSTEIN HJ, Curigliano G, Loibl S, Dubsky P, et al
    Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019.
    Ann Oncol. 2019 Aug 2. pii: 5543097. doi: 10.1093.
    PubMed     Text format     Abstract available

  5. SRINIVASALU VK, Susan A, Jose WM, Philip A, et al
    41P Prognostic significance of BCL-2 expression in triple negative breast cancer (TNBC).
    Ann Oncol. 2019 Aug 2. pii: 5543072. doi: 10.1093.
    PubMed     Text format    

  6. SRINIVASALU VK, Susan A, Philip A, Jose WM, et al
    147P Clinical significance of BCL-2 with basal and non-basal triple negative breast cancer (TNBC).
    Ann Oncol. 2019 Aug 2. pii: 5543073. doi: 10.1093.
    PubMed     Text format    


    Ann Surg

  7. BYUN HK, Chang JS, Im SH, Kirova YM, et al
    Risk of Lymphedema Following Contemporary Treatment for Breast Cancer: An Analysis of 7617 Consecutive Patients From a Multidisciplinary Perspective.
    Ann Surg. 2019 Jul 23. doi: 10.1097/SLA.0000000000003491.
    PubMed     Text format     Abstract available

  8. NEWMAN LA, Jenkins B, Chen Y, Oppong JK, et al
    Hereditary Susceptibility for Triple Negative Breast Cancer Associated With Western Sub-Saharan African Ancestry: Results From an International Surgical Breast Cancer Collaborative.
    Ann Surg. 2019 Jul 6. doi: 10.1097/SLA.0000000000003459.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  9. RIVERA-BUENDIA F, Franco-Cendejas R, Roman-Lopez CG, Colin-Castro CA, et al
    Randomized Controlled Trial to Reduce Bacterial Colonization of Surgical Drains with the Use of Chlorhexidine-Coated Dressings After Breast Cancer Surgery.
    Ann Surg Oncol. 2019 Jul 25. pii: 10.1245/s10434-019-07631.
    PubMed     Text format     Abstract available

  10. KRUG D, Lederer B, Seither F, Nekljudova V, et al
    Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials.
    Ann Surg Oncol. 2019 Jul 26. pii: 10.1245/s10434-019-07635.
    PubMed     Text format     Abstract available

  11. SAMIEI S, van Kaathoven BN, Boersma L, Granzier RWY, et al
    Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction.
    Ann Surg Oncol. 2019 Jul 29. pii: 10.1245/s10434-019-07643.
    PubMed     Text format     Abstract available

  12. SAWAKI M, Kodaira T, Iwata H
    ASO Author Reflections: The Strengths and Weaknesses of Intraoperative Radiotherapy for Early Breast Cancer and Ipsilateral Tumor Recurrence.
    Ann Surg Oncol. 2019 Jul 29. pii: 10.1245/s10434-019-07658.
    PubMed     Text format    

  13. BARTH RJ JR, Krishnaswamy V, Paulsen KD, Rooney TB, et al
    A Randomized Prospective Trial of Supine MRI-Guided Versus Wire-Localized Lumpectomy for Breast Cancer.
    Ann Surg Oncol. 2019 Jul 29. pii: 10.1245/s10434-019-07531.
    PubMed     Text format     Abstract available

  14. ZHANG F, Huang M, Zhou H, Chen K, et al
    A Nomogram to Predict the Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Laboratory Indicators.
    Ann Surg Oncol. 2019 Jul 29. pii: 10.1245/s10434-019-07655.
    PubMed     Text format     Abstract available

  15. MURPHY BL, Day CN, Hoskin TL, Habermann EB, et al
    Adolescents and Young Adults with Breast Cancer have More Aggressive Disease and Treatment Than Patients in Their Forties.
    Ann Surg Oncol. 2019 Aug 2. pii: 10.1245/s10434-019-07653.
    PubMed     Text format     Abstract available

  16. KANTOR O, Bao J, Jaskowiak N, Yao K, et al
    The Prognostic Value of the AJCC 8th Edition Staging System for Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer.
    Ann Surg Oncol. 2019 Aug 2. pii: 10.1245/s10434-019-07636.
    PubMed     Text format     Abstract available


    Anticancer Res

  17. GOTO W, Kashiwagi S, Asano Y, Takada K, et al
    The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines.
    Anticancer Res. 2019;39:4031-4041.
    PubMed     Text format     Abstract available

  18. MENDONCA P, Darwish AG, Tsolova V, El-Sharkawy I, et al
    The Anticancer and Antioxidant Effects of Muscadine Grape Extracts on Racially Different Triple-negative Breast Cancer Cells.
    Anticancer Res. 2019;39:4043-4053.
    PubMed     Text format     Abstract available

  19. KOLBERG HC, Uhl V, Massarut S, Holmes D, et al
    Targeted Intraoperative Radiotherapy During Breast-conserving Surgery for Breast Cancer in Patients After Implant Augmentation.
    Anticancer Res. 2019;39:4215-4218.
    PubMed     Text format     Abstract available

  20. TUOHINEN SS, Skytta T, Huhtala H, Virtanen V, et al
    Left Ventricular Speckle Tracking Echocardiography Changes Among Early-stage Breast Cancer Patients Three Years After Radiotherapy.
    Anticancer Res. 2019;39:4227-4236.
    PubMed     Text format     Abstract available

  21. SEDLOEV T, Vlahova A, Usheva S, Vasileva-Slaveva M, et al
    Long-Term Survival and Complete Response to Anastrozole in Breast Cancer Patient With Cutaneous Metastases Only.
    Anticancer Res. 2019;39:4393-4398.
    PubMed     Text format     Abstract available

  22. CHO O, Chun M, Kim SW, Jung YS, et al
    Lymphopenia as a Potential Predictor of Ipsilateral Breast Tumor Recurrence in Early Breast Cancer.
    Anticancer Res. 2019;39:4467-4474.
    PubMed     Text format     Abstract available


    BMC Cancer

  23. KOCIK J, Pajaczek M, Kryczka T
    Worse survival in breast cancer in elderly may not be due to underutilization of medical procedures as observed upon changing healthcare system in Poland.
    BMC Cancer. 2019;19:749.
    PubMed     Text format     Abstract available

  24. CARAYOL M, Ninot G, Senesse P, Bleuse JP, et al
    Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the "APAD1" randomized controlled trial.
    BMC Cancer. 2019;19:737.
    PubMed     Text format     Abstract available

  25. LATTANZIO R, Iezzi M, Sala G, Tinari N, et al
    PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes.
    BMC Cancer. 2019;19:747.
    PubMed     Text format     Abstract available

  26. BARRENO L, Caceres S, Alonso-Diez A, Vicente-Montana A, et al
    Vasculogenic mimicry-associated ultrastructural findings in human and canine inflammatory breast cancer cell lines.
    BMC Cancer. 2019;19:750.
    PubMed     Text format     Abstract available

  27. WANG H, Tan Z, Hu H, Liu H, et al
    microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1.
    BMC Cancer. 2019;19:738.
    PubMed     Text format     Abstract available


    Br J Cancer

  28. HARVIE M, Pegington M, McMullan D, Bundred N, et al
    The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial.
    Br J Cancer. 2019 Aug 1. pii: 10.1038/s41416-019-0522.
    PubMed     Text format     Abstract available


    Breast Cancer

  29. IGUCHI-MANAKA A, Okumura G, Ichioka E, Kiyomatsu H, et al
    High expression of soluble CD155 in estrogen receptor-negative breast cancer.
    Breast Cancer. 2019 Aug 1. pii: 10.1007/s12282-019-00999.
    PubMed     Text format     Abstract available

  30. NAKAGAWA A, Fujimoto H, Nagashima T, Sangai T, et al
    Histological features of skin and subcutaneous tissue in patients with breast cancer who have received neoadjuvant chemotherapy and their relationship to post-treatment edema.
    Breast Cancer. 2019 Jul 25. pii: 10.1007/s12282-019-00996.
    PubMed     Text format     Abstract available

  31. IIOKA Y, Iwata T, Yamauchi H
    Developing a checksheet for breast cancer patients receiving endocrine therapy-examining reliability and validity.
    Breast Cancer. 2019 Aug 2. pii: 10.1007/s12282-019-00998.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  32. KALLERGI G, Tsintari V, Sfakianakis S, Bei E, et al
    The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization.
    Breast Cancer Res. 2019;21:86.
    PubMed     Text format     Abstract available

  33. HUSS L, Butt ST, Borgquist S, Elebro K, et al
    Vitamin D receptor expression in invasive breast tumors and breast cancer survival.
    Breast Cancer Res. 2019;21:84.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  34. ZHANG L, Bailleul J, Yazal T, Dong K, et al
    PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation.
    Breast Cancer Res Treat. 2019 Aug 1. pii: 10.1007/s10549-019-05376.
    PubMed     Text format     Abstract available

  35. GOTTSCHAU M, Jensen A, Reinholdt K, Guleria S, et al
    Risk of breast cancer among women with benign ovarian tumors: a Danish nationwide cohort study.
    Breast Cancer Res Treat. 2019 Jul 30. pii: 10.1007/s10549-019-05369.
    PubMed     Text format     Abstract available

  36. ABRAMSON VG, Oliveira M, Cervantes A, Wildiers H, et al
    A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
    Breast Cancer Res Treat. 2019 Jul 31. pii: 10.1007/s10549-019-05360.
    PubMed     Text format     Abstract available

  37. VITIELLO GAF, Amarante MK, Banin-Hirata BK, Campos CZ, et al
    Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism in Brazilian breast cancer patients: association with susceptibility, clinicopathological features, and interaction with TGFB1 haplotypes.
    Breast Cancer Res Treat. 2019 Jul 30. pii: 10.1007/s10549-019-05370.
    PubMed     Text format     Abstract available

  38. ZHOU H, Wang XJ, Jiang X, Qian Z, et al
    Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.
    Breast Cancer Res Treat. 2019 Jul 30. pii: 10.1007/s10549-019-05375.
    PubMed     Text format     Abstract available

  39. HUANG W, Ran R, Shao B, Li H, et al
    Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2019 Jul 29. pii: 10.1007/s10549-019-05371.
    PubMed     Text format     Abstract available

  40. DEL RE M, Bertolini I, Crucitta S, Fontanelli L, et al
    Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
    Breast Cancer Res Treat. 2019 Jul 26. pii: 10.1007/s10549-019-05365.
    PubMed     Text format     Abstract available


    Breast J

  41. WALLACE AS, Keene KS, Williams CP, Jackson BE, et al
    Hypofractionated radiation in older women with breast cancer.
    Breast J. 2019 Jul 29. doi: 10.1111/tbj.13444.
    PubMed     Text format     Abstract available

  42. FARROKH D, Ameri L, Oliaee F, Maftouh M, et al
    Can ultrasound be considered as a potential alternative for sentinel lymph node biopsy for axillary lymph node metastasis detection in breast cancer patients?
    Breast J. 2019 Jul 29. doi: 10.1111/tbj.13475.
    PubMed     Text format    

  43. BAEKSTED CW, Nissen A, Knoop A, Christiansen M, et al
    Handling of symptomatic adverse events in breast cancer patients receiving adjuvant chemotherapy in a cluster randomized trial with electronic patient-reported outcomes as intervention.
    Breast J. 2019 Jul 28. doi: 10.1111/tbj.13477.
    PubMed     Text format    


    Cancer

  44. MANZ CR
    Getting in sync with adherence to endocrine therapy in breast cancer.
    Cancer. 2019 Aug 2. doi: 10.1002/cncr.32434.
    PubMed     Text format    

  45. NEUNER JM, Fergestrom NM, Laud PW, Nattinger AB, et al
    The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence.
    Cancer. 2019 Aug 2. doi: 10.1002/cncr.32433.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  46. PEER CJ, Schmidt KT, Kindrick JD, Eisner JR, et al
    A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.
    Cancer Chemother Pharmacol. 2019 Jul 31. pii: 10.1007/s00280-019-03908.
    PubMed     Text format     Abstract available

  47. FRAGUAS-SANCHEZ AI, Martin-Sabroso C, Fernandez-Carballido A, Torres-Suarez AI, et al
    Current status of nanomedicine in the chemotherapy of breast cancer.
    Cancer Chemother Pharmacol. 2019 Jul 31. pii: 10.1007/s00280-019-03910.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  48. ROSSI L, McCartney A, Risi E, De Santo I, et al
    Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.
    Clin Breast Cancer. 2019 Jun 11. pii: S1526-8209(19)30307.
    PubMed     Text format     Abstract available

  49. VAHEDNIA E, Shandiz FH, Bagherabad MB, Moezzi A, et al
    The Impact of CASP8 rs10931936 and rs1045485 Polymorphisms as well as the Haplotypes on Breast Cancer Risk: A Case-Control Study.
    Clin Breast Cancer. 2019 May 31. pii: S1526-8209(18)30646.
    PubMed     Text format     Abstract available

  50. LI H, Chen Y, Wang X, Tang L, et al
    T1-2N0M0 Triple-Negative Breast Cancer Treated With Breast-Conserving Therapy Has Better Survival Compared to Mastectomy: A SEER Population-Based Retrospective Analysis.
    Clin Breast Cancer. 2019 May 30. pii: S1526-8209(19)30316.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  51. ZHANG X, Zhao W, Wei W, You Z, et al
    Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer.
    Clin Cancer Res. 2019 Jul 26. pii: 1078-0432.CCR-18-4055.
    PubMed     Text format     Abstract available

  52. PAOLETTI C, Miao J, Dolce EM, Darga EP, et al
    Circulating Tumor Cell Clusters in Metastatic Breast Cancer Patients: a SWOG S0500 Translational Medicine Study.
    Clin Cancer Res. 2019 Jul 29. pii: 1078-0432.CCR-19-0208.
    PubMed     Text format     Abstract available

  53. DRAGO JZ, Formisano L, Juric D, Niemierko A, et al
    FGFR1 gene amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor positive (HR+) breast cancer.
    Clin Cancer Res. 2019 Aug 1. pii: 1078-0432.CCR-19-0138.
    PubMed     Text format     Abstract available


    Eur J Cancer

  54. GNANT M
    New evidence and hope for young patients with breast cancer.
    Eur J Cancer. 2019;118:166-168.
    PubMed     Text format    


    Eur J Surg Oncol

  55. CORSO G, Sacchini V, Pravettoni G, Veronesi P, et al
    Familial lobular breast cancer: Is testing for germline CDH1 mutations necessary?
    Eur J Surg Oncol. 2019 Jul 19. pii: S0748-7983(19)30578.
    PubMed     Text format    


    Eur Radiol

  56. KETTUNEN T, Okuma H, Auvinen P, Sudah M, et al
    Peritumoral ADC values in breast cancer: region of interest selection, associations with hyaluronan intensity, and prognostic significance.
    Eur Radiol. 2019 Jul 29. pii: 10.1007/s00330-019-06361.
    PubMed     Text format     Abstract available


    Int J Cancer

  57. MARCINIAK W, Derkacz R, Muszynska M, Baszuk P, et al
    Blood Arsenic Levels and the Risk of Familial Breast Cancer in Poland.
    Int J Cancer. 2019 Jul 26. doi: 10.1002/ijc.32595.
    PubMed     Text format     Abstract available


    J Clin Oncol

  58. CESPEDES FELICIANO EM, Chen WY, Bradshaw PT, Prado CM, et al
    Adipose Tissue Distribution and Cardiovascular Disease Risk Among Breast Cancer Survivors.
    J Clin Oncol. 2019 Aug 1:JCO1900286. doi: 10.1200/JCO.19.00286.
    PubMed     Text format     Abstract available


    Nature

  59. WELLENSTEIN MD, Coffelt SB, Duits DEM, van Miltenburg MH, et al
    Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.
    Nature. 2019 Jul 31. pii: 10.1038/s41586-019-1450.
    PubMed     Text format     Abstract available


    NPJ Breast Cancer

  60. MAZUMDAR A, Tahaney WM, Reddy Bollu L, Poage G, et al
    The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression.
    NPJ Breast Cancer. 2019;5:22.
    PubMed     Text format     Abstract available

  61. ABUBAKAR M, Guo C, Koka H, Sung H, et al
    Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression.
    NPJ Breast Cancer. 2019;5:20.
    PubMed     Text format     Abstract available


    Oncogene

  62. CASLINI C, Hong S, Ban YJ, Chen XS, et al
    HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells.
    Oncogene. 2019 Aug 2. pii: 10.1038/s41388-019-0897.
    PubMed     Text format     Abstract available


    Oncol Rep

  63. FAN C, Liu N, Fan S, Yang Z, et al
    Comprehensive multigene mutation spectra of breast cancer patients from Northeast China obtained using the Ion Torrent sequencing platform.
    Oncol Rep. 2019 Jul 30. doi: 10.3892/or.2019.7253.
    PubMed     Text format     Abstract available

  64. HONG Z, Hong C, Ma B, Wang Q, et al
    MicroRNA1263p inhibits the proliferation, migration, invasion, and angiogenesis of triplenegative breast cancer cells by targeting RGS3.
    Oncol Rep. 2019 Jul 26. doi: 10.3892/or.2019.7251.
    PubMed     Text format     Abstract available


    PLoS One

  65. GEBREMARIAM A, Addissie A, Worku A, Assefa M, et al
    Perspectives of patients, family members, and health care providers on late diagnosis of breast cancer in Ethiopia: A qualitative study.
    PLoS One. 2019;14:e0220769.
    PubMed     Text format     Abstract available

  66. SARKAR A, Chanda A, Regmi SC, Karve K, et al
    Recombinant human PRG4 (rhPRG4) suppresses breast cancer cell invasion by inhibiting TGFbeta-Hyaluronan-CD44 signalling pathway.
    PLoS One. 2019;14:e0219697.
    PubMed     Text format     Abstract available


  67. Expression of Concern: Hydrazinocurcumin Encapsuled Nanoparticles "Re-Educate" Tumor-Associated Macrophages and Exhibit Anti-Tumor Effects on Breast Cancer Following STAT3 Suppression.
    PLoS One. 2019;14:e0220672.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: